摘要
医药产业是资本和知识密集型产业,其国际竞争力和可持续发展必须建立在完备的国家药物创新体系之上。与此同时,明确医药企业作为药物研发和生产的定位,提高研发实力和增加创新投入,才能真正推动国家新药创新体系的发展。该文综述分析了中国药物创新体系的发展历程及医药企业创新在这个过程中的定位,从"重大新药创制"科技重大专项实施前后审视医药企业创新能力和定位的变化;从中国药物创新体系建设和现状来看,中国医药企业虽然有了较大的发展,但在药物创新水平方面与国际领先制药企业仍存在较大的差距。
The pharmaceutical industry is characterized by the intensive capital and knowledge. Its international competitiveness and sustainable development should be established on a complete national drug innovation system. At the same time, the development of new drug innovation system in China can be really promoted by the accurate location of pharmaceutical enterprises as research and development （R ＆ D） and production, the improved R ＆ D strength, as well as the increased investment in innovation. This paper reviews both the development of Chinese drug innovation system and the orientation of pharmaceutical enterprises innovation during this process. Furthermore, the changes of innovation capability and positioning of pharmaceutical companies have been investigated before and after the launch of the Drug Innovation Major Project. Although, the construction of Chinese pharmaceutical innovation system has greatly promoted the progress of our pharmaceutical companies, a wide gap in the level of drug innovation still exists between Chinese pharmaceutical enterprises and international leading drug companies in the world.
作者
柴慧婷
刘振明
王志锋
CHAI Huiting1, LIU Zhenming2, WANG Zhifeng1(1. School of Public Health, Peking University, Beijing 100191, P. R. China 2. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, P. R. Chin)
出处
《华西医学》
CAS
2018年第3期359-363,共5页
West China Medical Journal
基金
国家自然科学基金(21772005)
关键词
国家药物创新体系
医药企业创新
医药企业的定位
新药专项
National drug innovation system
Pharmaceutical enterprises innovation
The location of pharmaceutical enterprises
The Drug Innovation Major Project
